Danish biochemist and Chief Scientific Advisor at Novo Nordisk, widely credited as the key scientist behind the development of semaglutide (Ozempic/Wegovy) and the broader GLP-1 agonist program.
Led the scientific development of semaglutide — the GLP-1 receptor agonist that became Ozempic and Wegovy — creating the first weight loss drug with both efficacy and safety at a meaningful scale, launching the GLP-1 era in medicine.
Discussing
Ask anything about Lotte Bjerre Knudsen — their ideas, influences, contradictions, legacy.
Sign in to start a conversation.